Reported complete and overall response rates (CR and OR) in various clinical trials for chronic lymphocytic leukemia (CLL).
| Regimen . | Patients . | %CR . | %OR . | Ref. . |
|---|---|---|---|---|
| Chlorambucil | 181 | 3 | 37 | 32 |
| Fludarabine (Flu) | 170 | 20 | 70 | 32 |
| Flu+Cyclophosphamide (FC) | 34 | 35 | 88 | 34 |
| Flu+Rituximab (Concurrent) | 51 | 77 | 90 | 37 |
| (Sequential) | 53 | 28 | 77 | 37 |
| FC+Rituximab | 202 | 69 | 95 | 38 |
| Regimen . | Patients . | %CR . | %OR . | Ref. . |
|---|---|---|---|---|
| Chlorambucil | 181 | 3 | 37 | 32 |
| Fludarabine (Flu) | 170 | 20 | 70 | 32 |
| Flu+Cyclophosphamide (FC) | 34 | 35 | 88 | 34 |
| Flu+Rituximab (Concurrent) | 51 | 77 | 90 | 37 |
| (Sequential) | 53 | 28 | 77 | 37 |
| FC+Rituximab | 202 | 69 | 95 | 38 |